# CTI BIOPHARMA CORP

CTI BIOPHARMA CORP is a company headquartered in Seattle, WA, United States.

## Company overview

- **Legal name:** CTI BIOPHARMA CORP
- **Former names in filing history:** CELL THERAPEUTICS INC (1996-06-28 to 2014-05-29)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Seattle, WA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000891293

## About

CTI BIOPHARMA CORP is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000891293, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2023-03-06, it reported annual revenue of USD 53,948,000; net income of USD -92,992,000; total assets of USD 125,925,000 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $53.9M (USD 53,948,000)
- **Net income:** -$93.0M (USD -92,992,000)
- **Total assets:** $125.9M (USD 125,925,000)
- **Cash and equivalents:** $30.4M (USD 30,420,000)
- **Operating cash flow:** -$81.2M (USD -81,194,000)

### FY2021 (period ended 2021-12-31)

- **Net income:** -$97.9M (USD -97,908,000)
- **Total assets:** $72.4M (USD 72,434,000)
- **Cash and equivalents:** $65.4M (USD 65,446,000)
- **Operating cash flow:** -$84.9M (USD -84,889,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$52.5M (USD -52,451,000)
- **Total assets:** $58.2M (USD 58,241,000)
- **Cash and equivalents:** $40.4M (USD 40,394,000)
- **Operating cash flow:** -$42.2M (USD -42,205,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $3.3M (USD 3,345,000)
- **Net income:** -$40.0M (USD -40,020,000)
- **Total assets:** $46.3M (USD 46,280,000)
- **Cash and equivalents:** $31.1M (USD 31,144,000)
- **Operating cash flow:** -$27.8M (USD -27,822,000)

## Recent SEC filings

- Form 8-K — filed 2023-06-26 — period 2023-06-24 — 8-K
- Form 8-K — filed 2023-05-30 — period 2023-05-30 — 8-K
- Form 10-Q — filed 2023-05-15 — period 2023-03-31 — 10-Q
- Form 8-K — filed 2023-05-10 — period 2023-05-10 — 8-K
- Form DEF 14A — filed 2023-04-28 — period 2023-06-21 — DEF 14A
- Form SC 13G — filed 2023-04-13
- Form SC 13G — filed 2023-03-24
- Form 10-K — filed 2023-03-06 — period 2022-12-31 — 10-K
- Form 8-K — filed 2023-03-06 — period 2023-03-06 — 8-K
- Form SC 13G — filed 2023-02-03
- Form 10-Q — filed 2022-11-07 — period 2022-09-30 — 10-Q
- Form 8-K — filed 2022-11-07 — period 2022-11-07 — 8-K

---

Updated: 2026-10-23T20:09:28Z

Canonical page: https://altss.com/profile/cti-biopharma-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology